Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Medical features of COVID-19 and influenza infection: A comparative study in Paris, France.
Faury H, Courboulès C, Payen M, Jary A, Hausfater P, Luyt C, Dres M, Pourcher V, Abdi B, Wirden M, Calvez V, Marcelin AG, Boutolleau D, Burrel S. Faury H, et al. Among authors: wirden m. J Infect. 2021 Feb;82(2):e36-e39. doi: 10.1016/j.jinf.2020.08.017. Epub 2020 Aug 14. J Infect. 2021. PMID: 32798533 Free PMC article. No abstract available.
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Marcelin AG, Lamotte C, Delaugerre C, Ktorza N, Ait Mohand H, Cacace R, Bonmarchand M, Wirden M, Simon A, Bossi P, Bricaire F, Costagliola D, Katlama C, Peytavin G, Calvez V; Genophar Study Group. Marcelin AG, et al. Among authors: wirden m. Antimicrob Agents Chemother. 2003 Feb;47(2):594-600. doi: 10.1128/AAC.47.2.594-600.2003. Antimicrob Agents Chemother. 2003. PMID: 12543665 Free PMC article. Clinical Trial.
Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs.
Wirden M, Simon A, Schneider L, Tubiana R, Paris L, Marcelin AG, Delaugerre C, Legrand M, Herson S, Peytavin G, Katlama C, Calvez V. Wirden M, et al. J Clin Microbiol. 2003 Jun;41(6):2713-5. doi: 10.1128/JCM.41.6.2713-2715.2003. J Clin Microbiol. 2003. PMID: 12791913 Free PMC article.
Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Marcelin AG, Dalban C, Peytavin G, Lamotte C, Agher R, Delaugerre C, Wirden M, Conan F, Dantin S, Katlama C, Costagliola D, Calvez V. Marcelin AG, et al. Among authors: wirden m. Antimicrob Agents Chemother. 2004 Dec;48(12):4687-92. doi: 10.1128/AAC.48.12.4687-4692.2004. Antimicrob Agents Chemother. 2004. PMID: 15561845 Free PMC article.
Clinically relevant genotype interpretation of resistance to didanosine.
Marcelin AG, Flandre P, Pavie J, Schmidely N, Wirden M, Lada O, Chiche D, Molina JM, Calvez V; AI454-176 Jaguar Study Team. Marcelin AG, et al. Among authors: wirden m. Antimicrob Agents Chemother. 2005 May;49(5):1739-44. doi: 10.1128/AAC.49.5.1739-1744.2005. Antimicrob Agents Chemother. 2005. PMID: 15855490 Free PMC article. Clinical Trial.
121 results